Actelion

This program provides selexipag (Uptravi) to a single patient with Buerger's disease who has a wound that won't heal. The goal is to see if the drug can help control the disease and heal the wound. This is not a cure, but a way to manage the condition.

This study tests whether a higher dose (75 mg) of the drug macitentan works better than the usual dose (10 mg) at preventing serious events like hospitalization or death in people with pulmonary arterial hypertension (PAH). About 935 adults with PAH will take either the higher or…

This study is testing the safety and proper dosing of selexipag in children aged 2 to 17 with pulmonary arterial hypertension (PAH), a serious lung condition that makes it hard for the heart to pump blood. Researchers want to find the right starting dose that gives children simil…

This study tests whether adding selexipag to standard treatment can delay disease worsening in children aged 2 to 18 with pulmonary arterial hypertension (PAH), a serious lung condition. About 138 children will receive either selexipag or a placebo alongside their usual care. The…